Wells Fargo analyst Stephen Baxter raised the firm’s price target on Agilon Health to $28 from $22 and keeps an Overweight rating on the shares. Commentary on 2024 expectations was better-than-feared, given the potential headwinds from proposed MA rates and risk model changes, the firm notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGL: